Literature DB >> 17579945

Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al.

Christopher McCabe, Aki Tsuchiya, Karl Claxton, James Raftery.   

Abstract

Mesh：

Year:  2007        PMID： 17579945     DOI： 10.1017/s0266462307071012

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN： 0266-4623            Impact factor:   2.188


× No keyword cloud information.
  6 in total

1.  Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67.

Authors:  Arna S Desser; Dorte Gyrd-Hansen; Jan Abel Olsen; Sverre Grepperud; Ivar Sønbø Kristiansen
Journal:  BMJ       Date:  2010-09-22

Review 2.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 3.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

4.  Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

Authors:  Malek B Hannouf; Chander Sehgal; Jeffrey Q Cao; Joseph D Mocanu; Eric Winquist; Gregory S Zaric
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

5.  Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.

Authors:  Andrea Messori
Journal:  Sci Pharm       Date:  2016-01-24

Review 6.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.